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Intestinal failure is defined by the inability to maintain a normal nutri-
tional status (caloric intake. fluids and electrolytes. weight. etc) by use of 
the gastrointestinal tract alone. Prior to the introduction of total parenteral 
nutrition (TPN) 1 the survival of these patients relied on the ability of the 
remaining bowel to undergo adaptation. The use of TPN has provided 
significant improvement in outcome (65-80% for 3 year survival);2 this will 
vary. however. according to the etiology of the intestinal failure. Limiting 
factors have been the induction of liver dysfunction and cirrhosis secondary 
to TPN. and venous access complications of which infection and the pro-
gressive inability to cannulate are the most severe. Also, the expense of life 
time therapy with TPN has been estimated at between $75.000 to $150.000 
per year. 3 Though some patients enjoy a normal lifestyle on TPN. many 
individuals are hampered by the constant hospitalizations for complications. 
and suffer from significant social stigmata derived from incomplete rehabili-
tation into society. 
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Experimental transplantation of the small bowel was first reported as an 
isolated organ graft by Lillehei in 1959.4 and one year later as parr of a 
multivisceral graft_5 Though liver transplantation was also in the experimen-
tal phase at this time. the clinical applicability of this procedure was rapidly 
expanded after the introduction of cyclosporine A. This did not occur however 
with intestinal transplantation where numerous clinical trials performed 
between 1964 and 1987 were met with almost unanimous failure.6 Failure 
of this modality was attributed to rejection of the intestinal graft, sepsis, or 
technical imperfections. It was not until 1987 when a 3-year-old girl re-
ceived a multivisceral abdominal graft that contained the stomach, duode-
num, pancreas, small bowel, colon. and liver that an extended survival with 
intestinal graft: function of 6 months was attained.! An even longer survival 
was subsequently obtained (greater than 1 year) in a recipient of a liver and 
small bowel graft: treated by Grant et al.B Until 1990, there were only two 
survivors of isolated cadaveric intestinal grafts, one in France and the other 
in Germany.9.IO 
INDICATIONS 
Small bowel transplantation, either alone or accompanied by the liver, 
may be beneficial in any patient with intestinal failure who is dependent on 
TPN for their survival. The clinical outcome under standard therapy (TPN) 
is mainly a reflection of the underlying diagnosis, and reflects septic, meta-
bolic, and hepatic complications. The causes for intestinal failure are varied, 
age dependent, and can be temporary or permanent. The loss of intestinal 
function may be acute as in intestinal infarctions (necrotizing enterocolitis, 
volvulus. mesenteric thrombosis), or chronic (Crohn's disease, radi3tion 
enteritis etc). 
In some p3tients ad3ptation of the remaining intestine permits recovery 
3fter a period of temporary TPN support. The minimum length of intestine 
required for maintenance of nutritional status has nor been established. 
Reporrs advocating 10-20 em of small intestine with an ileocecal v3lve, 3nd 
40 cm withoutl!.ll reflect clinical management experience. Adequate func-
tion of rem3ining intestine depends not only on the length of bowel. but 
also the morphology of the intestinal mucosa (both gross and histologic). 
Motiliry disorders. gut hormone interrelationships, biliary and fat metabo-
lism, ;lS well 3S intestinal microtlora are important cotacrors. The presence 
of residual ileum (for its adaptive qualities), ileocecal valve (the slowing of 
inrestin3l transit time) and the colon (increased water absorption) also enrer 
into the equation. 
Candidates with intestinal failure can be divided into those with surgi-
cal and nonsurgical etiology. This division has implications with regards to 
the rype of transplant to be pertormed. Patients with surgical causes sutfer 
from loss of bowel from intestinal atresias. infarctions consequent to volvulus, 
necrotizing enterocolitis, vascular catastrophes ({fauma or thrombosis). 
Crohn's disease. ete. Nonsurgical causes of intestinal bilure have included 
motiliry disorders such as intestinal pseudoobstruction syndromes. absorp-
tive insufficiency as seen in microvillus inclusion disease. polyposis syn-
tiromes with chronic bleeding and protein losing entcropathy, and inc;uccr-
ating dcsmoid tumors. 
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Table 11.1. Small intestinal transplantation referrals 1990 to 1992 
Pediatric 
Number of referrals 83 
Diagnosis of pediatric patients Diagnosis of adult patients 
Necrotizing Enterocolitis 21 Crohn's disease 
Gastroschisis 15 Thrombolytic disorder 
Volvulus 12 Trauma 
Pseudoobstruction 9 Pseudoobstruction 
Hirschsprung's disease 5 Radiation enteritis 
Intestinal atresia 5 Desmoid tumor 
Microvillus inclusion disease 2 Familial polyposis 
Malrotation 2 Volvulus 
Other 12 Other 
Adults 
88 
24 
19 
12 
7 
5 
4 
3 
3 
11 
Table 11.1 lists the indications tor intestinal transplantation at the Univer-
sity of Pirtsburgh in adults and children between May 1990 to Januaty 1993. 
Patients presenting with intestinal fuilure and TPN induced liver disease are 
candidates for liver/small bowel transplantation. Guidelines used in assessing the 
need for a concomitant liver transplant has been the degree of liver dysfunction 
(hyperbilirubinemia. rransaminase abnormalities. hypoalbuminemia. and 
coagulopathy) severity of fibrosis on liver biopsy. and the presence of portal 
hypertension as manifested by hepatosplenomegaly. ascites and esophageal va-
rices. Patients who have suffered mesenteric vascular thrombosis secondary to 
deficiencies of proteins S and C (hepatic derived) should also receive a concomi-
tmt liver transplant to provide tor these proteins. u 
Of 34 patients transplanted at the University of Pittsburgh during this 
time period. 22 presented in terminal stage of intestinal failure with total 
bilirubin levels between 2.3 and 50. and evidence of portal hypertension 
(bleeding esophageal varices). Septic complications had been seen in all 
patients. Similar patients should be transplanted as soon as evaluation is 
completed. Sudden unpredictable deterioration has led to the demise of 29 
out of 171 patients referred. Choosing the optimum time tor transplanta-
tion of the intestine alone is difficult since the clinical course and life 
expectancy are variable. It has been our policy to select patients that have 
persistent liver function test abnormalities (no synthetic dysfunction) with 
changes on liver biopsy (mild fibrosis. esteatosis. cholestasis) reHecting TPN 
injury. Also. patients who have had multiple septic episodes from line in-
fection and consequent thrombosis of access sites. and who are progressively 
depleting these sites should also be considered for intestinal transplantation. 
EVALUATION OF CANDIDATES 
Areas that must be covered when evaluating a potential small bowel 
transplant recipient include diagnosis. nutritional history and present nutri-
tional status. and possible recipient anatomic abnormalities (both gastrointes-
tinal and vascular). This should allow for accurate planning of graft type. 
however. the tlnal decision may be made at the time of exploration. 
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A complete understanding of the etiology for the intestinal failure. as 
well as knowledge of all previous operative procedures performed is para-
mount to a successful operation. Assessing for anatomic and functional 
integrity of the remaining gastrointestinal tract can be accomplished by 
routine barium tests. motility studies and absorption studies when indi-
cated. All pathologic specimens available should be reviewed. Review of 
infectious complications will guide prophylactic antibiotic therapy and 
possible need for gut decontamination. 
With the present sophistication of multivisceral harvesting techniques 
and graft acceptance the intestine can be transplanted with other organs 
such as the liver. stomach. duodenum. pancreas and colon. The graft type 
will depend on the individual evaluation focusing on functional integrity of 
the gut and the presence of pathology in the other abdominal organs. The 
Table 11.2. Evaluation protocol for intestine and other abdominal organ 
transplants 
Assessment of disease status 
History and physical examination: 
Etiology of intestinal failure 
Previous surgeries 
Associated anomalies 
Assessment of other organs 
Radiology: 
Upper and lower GI barium studies 
Liver Ultrasound 
Chest roentgenogram 
Absorption Studies: 
l)-Xylose absorption test 
;-~ hour tccal fat test 
Routine Laboratory Data: 
Hemoglobin. Icukocytc count 
,1nd diffcrential count 
Platclct count. prothrombin time. 
partial thromboplastin time 
Bilirubin. alkaline phosphatase. 
serum glutamic-pyruvic 
transaminase (SGPT). 
aspirate aminotransferase (AST) 
f'rotcln electrophoresis 
Alpha ictoprotcln 
Urinalysis 
Assessment of nutritional status 
Nutritional evaluation: 
Weight. height. triceps. skiniold. 
midarm circumference 
Transferrin. albumin. prealbumin 
serum amino acid. analysis 
Vitamins A. D. E. B,v Thiamine 
Triglyccndcs 
Specific transplant 
& infection work-up 
Immunological Studies: 
Blood Type (ABO) 
Tissue typing 
Cross matching 
Investigations for Infection: 
Blood. urine. throat. tcces. 
ascites culture: bacterial. fungal. 
viral 
Hepatitis screen 
Quantitative stool cultures 
Blood urea nitrogen (BUN). serum creatinine 
24 hour creatinine clearance 
liver Biopsy (when indicated) 
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typical case is that of TPN cholestatic liver disease leading to end stage liver 
failure. Assessment of hepatic integrity is by standard liver transplant pro-
tocols (jaundice. synthetic function analysis, presence of portal hyperten-
sion). Patients with motility disorders involving the entire gastrointestinal 
tract are candidates for replacement of this entire system. Also. patients with 
end stage liver disease and concomitant thrombosis of the entire splanchnic 
venous system. a heretofore contraindication for liver transplantation alone. 
can now potentially be saved with a complete multivisceral transplant. 
A thorough nutritional evaluation should be performed to better under-
stand existing problems (obesity. vitamin deficiencies. eating disorders. etc) and 
correct them prior to transplantation. This includes baseline anthropometries 
and laboratory data. A detailed summary is provided in Table 11.2. 
THE DONOR OPERATION 
All referrals for potential liver donation are also considered for possible 
small intestinal donation. The donor is usually of similar or smaller size 
than the recipient, and the ABO blood group should be identical; the HLA 
Intestinal Decontamination (Donor and Recipient) 
< Than 5 Years 5-12 Years 
AmphoteriCin B '00 mg 250 mg 
Tobramycln 10 mg 40 mg 
f'Olymycln E 25 mq 50 mg 
Systemic Antibiotics· 
Celota"me 25 mg I<g aose Q 8 hrs IV 
Amp'Cillin - 25 mg I<g aose Q 6 hrs IV 
>12 Years 
500 mg 
80 mq 
'00 Mq 
"'1 '''e ,eCIOtent !"JS r"iaC] recenl oae!erldl or lun(1allnfectJons p'ese 
"Iectlous agenls <;'"'Oy,O O~ CO .... e't"O ,'" !"'t' orOD"YIJChC ft'Q1men 
matching is random. 
Adequacy of the in-
testine is assessed by 
the donor team at the 
time of surgery. De-
tails of the technique 
and donor prepara-
tion are as oudined in 
Figure 11.1. Mcch-
;lOical preparation of 
the intestine is not 
performed prior to 
the donor operation. 
rig. 11. 1. The multivisceral 
harvest should allow for 
f7exibility not only for the 
,lbdominal procedure but 
Jlso for the thoracic or-
gan procurement Sepa-
rate infUSion of preserva-
tion lIuid (inset) allows for 
complete blanching of the 
liver graft IntestinJI de-
contamination is begun 
on the donor at the time 
of acceptance, and con-
tinued in the reCIpient for 
J pertod of 4 weeks. 1\('-
prmted with permiSSIon 
from Starzl, TE. The many 
faces of mu/tivisccral 
transplantatIOn. Surg, 
Cvnecol Obestet 1991; 
172:335-344. ©/ACS 
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The configuration of the organs to be harvested is wually designated 
after recipient evaluation, however some patients present the potential for 
unperceived operative findings. Therefore the procurement procedure should 
remain flexible, allowing for any final dissection to be done at the back 
table. The graft may consist of the full multivisceral clwter (liver, stomach, 
duodenum, pancreas, small bowel, and colon), or any combination that 
may be needed. 14 In most cases a clear limitation of the organs is known 
prior to transplant. The recovery time is approximately 4 hours. 
Harvesting of the multivisceral graft requires encirclement of the proxi-
mal aorta near the diaphragm for later cross clamping, and the distal aorta 
below the origin of the inferior mesenteric artery for insertion of the canula 
needed for the infusion of the cold preservation solution (University of 
Wisconsin solution). When only a liver/small bowel graft is required a 
standard hilar dissection similar to that used for an isolated liver graft is 
performed.' S The ascending and transverse colon are mobilized to isolate 
the small intestine which is divided with a stapler at the ligament of Treitz 
and just proximal to the ileocecal valve. Exposure of the portal and superior 
mesenteric veins is accomplished by dividing the pancreas immediately over 
these vessels and ligating all branches from it. After clamping of the proxi-
mal aorta in situ arterial perfusion is accomplished via the aortic cannula 
and the venous bed is decompressed using a suprahepatic caval venotomy. 
The liver can also be perfused separately through a cannula inserted into the 
superior mesenteric vein or the splenic vein. Back table irrigation of the intes-
tinal lumen is not necessary in small bowel or liver/small bowel transplantation 
and is only required when the colon is included in the graft. Manipulation of 
the graft lymphoreticular tissue (ALG. OKT3. or irradiation) is not performed. 
In situations where only a small bowel graft is required the liver may be sepa-
rated from the graft in situ after perfusion. or at the back table.'6 
THE RECIPIENT OPERATION 
Once the donor team contlrms adequacy of the donor organs the recipi-
ent is brought to the operating room for exploration. This usually requires 
hours of careful dissection through adhesions. focusing on the status of the 
liver and the preservation of remaining bowel. The final decision as to the 
needs of the patient in terms of organs can be made at this time. If the liver 
is to be removed the hepatic hilus is exposed. and the liver is devascularized 
by ligating the hepatic arterial branches. The common bile duct is ligated 
and the portal vein is exposed. A portacaval shunt is performed to allow tor 
decompression of the remaining splanchnic organs (stomach. duodenum. 
pancreas. spleen),'? In a recipient of a multivisceral graft this is not required 
since all of the native organs are removed. 
Removal of the liver can be accomplished with removal of the retrohepatic 
vena cava (as for a standard orthotopic liver transplant) or in a "piggy back" 
fashion (preserving the retrohepatic vena cava).'8 Most patients with intes-
tinal failure have had previous resections and we attempt to preserve as 
much normal residual small bowel and colon as possible. In patients with 
malabsorptive or intestinal pseudoobstructive syndromes all of the small 
intestine and colon are removed. 
Revascularization of the donor multivisceral or liver/smail bowel graft is 
accomplished by anastomosing the carrel patch containing the celiac and 
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superior mesenteric arteries to the recipient infrarenal aorta. An interposi-
tion graft of donor thoracic or abdominal aorta may be required. Venous 
drainage of the graft is into the hepatic veins of the recipient or by replace-
ment of the retrohepatic vena cava. The portacaval shunt may remain per-
manently, or it can be taken down and a recipient portal vein to donor 
portal vein anastomosis performed. This provides drainage of important 
hepatotrophic factors ftom the native pancreas into the hepatic graft. Venous 
drainage of the isolated small bowel graft can be into the native superior 
mesenteric vein, junction of the splenic vein/mesenteric vein below the 
pancreas, portal vein at the level of the hepatic hilus, or inferior vena cava.!? 
The venous drainage clamps are removed only after complete perfusion 
of the organs, allowing bleeding to occur from the superior mesenteric vein 
(isolated small bowel graft) or from the infrahepatic vena cava (liver/small 
bowel or multivisceral graft). Reconstruction of the gastrointestinal tract is 
performed using conventional techniques. A proximal tube jejunostomy is 
pertormed to drain the proximal intestine, and can be used subsequently for 
enteral nutrition. Biliary reconstruction is required only in the liver/small 
bowel recipients and is performed to the most proximal end of the trans-
planted jejunum. Figure 11.2 outlines the basic procedures described above. 
The pmential to transplant the entire gastrointestinal tract without the liver 
(sromach, duodenum, pancreas, small bowel and colon) has already been 
realized recently in a patient with multiple familial polyposis, the details of 
which however will not be described in this report. 
IMMUNOSUPPRESSION 
FKS06 (0.15-0.2 mg/kg/day) is given by continuous ill(f;J.vmous inlu-
sion immediately after graft revascularization, targeting !t:vels at between 2 
~md 3 ng/ml. Oral FKS06 is started once intestinal motility is present and 
integrity of the intestinal anastomosis' is confirmed by contrast barium 
studies. Since FKS06 absorption is independent of biliary enteroheparic 
circulation, maintenance of adequate levels on oral dosage alone is possible 
early in the postoperative course. 20 One gram of intravenous Hydrocorti-
sone (children) or methylprednisolone (adults) is given irmaoperatively. A 
steroid taper of methylprednisolone is started at a dose of 100 mg (children) 
or 200 mg (adults) and reduced over a period of 5 days to 10 mg (children) 
or 20 mg (adults) per day. Prostaglandin EI (Prostin) is administered at 
0.003 to 0.009 micrograms/kg/minute intraoperatively and tl1m LOlHinued 
lor') days. This is given less tor its immunosuppressive properties than lor 
the beneficial effect upon FKS06 nephrotoxicity.2! 
Craft rejection (liver and or small bowel) is treated initially with steroid 
therapy (intravenous hydrocortisone or methylprednisolone) as a bolus alone in 
LaSes of mild rejection, and with a steroid taper in ClSes of moderate ro severe 
rejection. Optimization of FKS06 trough levels should be pedormed by either 
increasing the baseline oral FKS06 dose or using supplemental intravenous 
I:KS06. Rejection of the small bowel can alter FKS06 absorption. The USe of 
OKT3 is rhe next line of therapy when rejeaion has progressed on J steroid 
taper. however. this should be considered earlier if there is evidence of impend-
ing mucosal extoliation (Fig. 11.3). Azathioprine is used to supplement baseline 
immunosuppression in cases of recurrent rejection. ;lnd where reJw.:tion of (he 
FK506 dose is necessary because of nephrotOxicity. 
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Long term immunosuppressive management has entailed reduction of 
FK506 dose (independent of the level), and stopping steroid therapy if the 
patient is clinically well and with a normally functioning graft. Although 
cocktail therapy is used for induction, most pediatric patients can be man-
aged eventually by mono therapy with FK506. 
POSTOPERATIVE CARE AND RESULTS 
The results reported herein pertain to 34 patients who received intes-
tinal transplants. There were 18 female and 16 male patients, with ages 
ranging between 6 months and 50 years. Twenty patients had combined 
liverlintestine transplants. 10 patients had isolated intestine transplants. and 
4 patients had multivisceral transplants. The followup time ranged between 
5 months and 3 years. The specifics of this patient population with their 
outcome is detailed in Table 11.3. 
Patients receiving a combined liver/small bowel graft are usually in 
significant liver failure and demand the same level of intensive care as a liver 
transplant recipient. They usually require a more prolonged period of ven-
tilatory support and consequently an extended intensive care unit stay. 
Broad spectrum intravenous antibiotics are given to the recipient for a 
period of 5 days postoperatively. If there is a history of nosocomial infec-
tions just prior ro rransplanr (bacterial and fungal), appropriate prophylaxis 
should be given. Assessment of pulmonary status, infection surveillance. 
liver graft function. and general preservation of homeostasis is as per routine 
post liver transplant protocols. 
Monitoring of rhe inrestinal graft focuses on multiple daily clinical 
evaluations, noting the character of the intestinal graft stoma for texture, 
Clinical SBTX 
Treatment of Rejection 
Histological Grade 
Mild 
Moderate 
Severe 
Treatment 
None 
FK 506, increase 
Steroids, bolus 
FK 506, increase 
Steroids, recycle 
FK 506, increase 
Steroids, bolus/recycle 
OKT3 
ri~. } 1.3. The treatment at mteSlmal allograft re,ection accordmg to seventy has bl't'n 
'lIcccsswl. however overlap dnd rapid evo/lllJon of seventy IS not uncommon. 
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Table 11.3. Postoperative results in small bowel transplantation 
fi ~ m IlI~CitllgSIS ~ SL!Bl!Il!~L :r.ett 
1 3.2 F NEe SB/l >966 Free 
2 4.3 M Gastroschisis SB/l >843 Free 
3 2.8 M Intestinal atresia SB/l 385 Died/lP 
4 0.6 F Intestinal atresia SB/l 23 Died/GVHD 
5 1.1 F Volvulus SB/l > 584 Free 
6 1.7 F Volvulus SB/l > 582 Free 
7 2.5 F Microvillus inclusion SB > 502 Free 
8 1.3 M Intestinal atresia SB > 447 Free 
9 10.2 F Pseudoobstruction SB > 375 Free 
10 1.5 M NEC SB/l 70 Died/MOF 
11 4.2 F Gastroschisis SB/l > 279 Free 
12 1.4 M Gastroschisis SB/l 29 Died/Sepsis 
13 0.8 M Microvillus Inclusion SB/l > 238 Free 
14 0.5 M Gastroschisis SB/l > 232 Free 
15 4.0 F Pseudoobstruction MV > 134 Free 
16 3.6 M NEC SB/l 97 Died/Sepsis 
17 0.9 F Gastroschisis SB/l > 92 Free 
18 15.5 M Volvulus SB/l > 71 Free 
19 31 M Gunshot wound SB 776 Died/Sepsis' 
20 26 F SMA thrombosis SB/l > 956 Free 
21 21 M Traffic accident SB/l > 573 Partial 
22 32 M CA & SMA thrombosis MV > 519 Partial 
23 50 F Crohn's disease SB > 444 Free 
24 34 F Desmoid tumor SB > 407 Total" 
~5 38 M Crohn's disease sB 376 Died/Sepsis 
26 '') F Crohn's disease sB > 369 Free 
27 25 M Crohn's disease sB/l > 353 Free 
28 29 F Desmoid tumor SB/l > 295 Free 
29 24 M CA & SMA thrombosis MV > 292 free 
30 20 F Traffic accident SB > 282 free 
31 32 F CA & SMA thrombosis MV > 217 Free 
32 19 M Traffic accident SB/l > 214 Free 
33 44 F SMA thrombosis SB/l > 190 Free 
34 37 F Familial polyposis SB > 109 Free 
, Retransplantation at 22 months ,. Graft removed at 8 months 
color. and friability. The stomal output is assessed for volume. consistency. 
and the presence of reducing substances as tested by pH and clinitest (re-
flecting possible rejection. viral/bacterial infections. or malabsorption). and 
the presence of blood (seen with rejection or infections). Endoscopic evalu-
ations are performed through the transplant ileostomy and also with upper 
endoscopy to assess the proximal transplanted bowel. This is pertormed 
twice a week for the first month and whenever clinicallv indicated thereat:. 
ter; mucosal biopsies should be a minimum of 5 samples.~1 
Intestinal allograft rejection may be asymptomatic. but generally pre-
sents with a combination of fever. abdominal pain and distention. nausea 
or vomiting. and a sudden increase in stomal output. Severe rejection can 
progress to gratt ileus and absence of stomal OUtpUt. as well as intestinal 
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bleeding from mucosal sloughing. Translocation of bacreria through the 
injured epithelium can precipitate a septic shock picture. This represents 
one of the few siruations in transplantation where tteatment entails aggres-
sive infectious and immunologic work-up focusing treatment on the specific 
infectious etiology, but more importantly additional immunosuppression 
for the treatment of graft rejection. Intestinal decontamination is continued 
(or reinstituted) during episodes of rejection. 
GRAfT REJECTION 
Acute rejection of the intestinal graft is suspected by endoscopic obser-
vations of mucosal edema. erythema, and friability as evidenced by in-
creased bleeding upon biopsy. The mucosa can loose its fine velvety appear-
ance and go on [0 become ischemic or dusky, with focal ulcerations. Severe 
rejecrion can present a granular mucosal pattern with diffuse ulcerations. or 
sloughing of large areas of mucosa. accompanied by a loss of peristalsis. 
The histologic criteria for the diagnosis of acute intestinal allografi: 
rejection includes edema of the lamina propria with mononuclear cell infil-
trates (small andlor blastic lymphocytes). villous blunting and cryptitis. 
Neutrophils, t:osinophils. and macrophages may be st:en traversing the 
muscularis mucosa.':.1 The degree of epithelial cell necrosis was variable ac-
cording to the severity of rejection; necrosis and regeneration are necessary 
components for the diagnosis of rejection. Complete mucosal and crypt 
destruction are seen in patients with severe rejection. The mucosal surtace 
can be replaced bv granulation tissue and inflammatory pseudomembrane!>. 
Chronic rejection has been seen in two patients after severe acute rejec-
tion. and is characterized by villous blunting. focal ulcerations, and epirhe-
lial metaplasia. Clinicallv there is chronic weight loss. with intermittem 
diarrhea. fever and blood loss. Mesenteric angiography in one such patient 
has revealed segmental narrowing of the mesenteric arteries.':" 
The incidence of acute intestinal allograft rejection has been reporred to 
he 80% in rhe isolated small bowel recipients. and /";"'01> in the liver/small 
bowel recipients: the incidence of acute liver allograft rejc:ction in the liver! 
small bowel recipients was 55% . .!3 
NUTRITIONAL SUPPORT 
Nutritional support was accomplished initially by using standard TPN 
solurions which was tapered gradually as oral or enteral feedings (via the jejunal 
tubel were tolerated. Feeding was started alter upper gastrointestinal barium 
studies confirmed a saristacrory intestinal anastomosis and good motility. En-
teral feeding is [he rule after intestinal transplantation since most patients do not 
voluntarilv ingest an adequate amount of calories early on. This has been par-
ticularlv important in pediatric recipients since they characteristicallv have poor 
or no oral intake. The specifiCS of this eating disorder is still under evalu:uioll, 
however. hcrors such as never having been fed before (and thus never learning), 
.1 hvper-gag rdlex trom lack of eating. and [he association of a noxIous feeling 
with the act of eating are important bctors. Tube feedings were commenced 
using Peptamen, which is an isotonic dipeptide formula containing mcdium 
chain triglycerides and glutamine. Peptamen was later convcned in children to 
Complete B which is a lactose gluten tree diet conraining dietary fibers to 
promme normalization of intestinal motility and function. 
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Weight Change in Children After SBTx 
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Height Change in Children After SBTx 
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Figs. 11.4 A - 11.48. Weight and height has been consIstently good in the pediatrIC palJents 
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Continuous feedings can be given by either a nasogastric or nasoduodenal 
rube, gastrostomy rube (with extension rube past the pylorus), or jejunostomy 
rube (into the transplanted bowel). The stomal output is assessed for vol-
ume pH and the presence of reducing substances as well as for quantitative 
bacterial cultures. Recipients of liver/small bowel grafts usually require a 
mean of 60 days to become independent of TPN, whereas isolated small 
bowel allograft recipients have become independent of TPN 30 days 
posttransplant. Weight and height increases between transplant and latest 
followup have been consistendy good in the children (Figs 11.4A and 11.4B), 
however some adults have lost weight after transplantation (Fig. 11.5). This 
has been due to a lesser adaptability to oral intake in some multivisceral 
recipients, and also to the presence of mild to moderate obesity pretrans-
plant in others. ~5 
Function has been assessed through the absorption of D-xylose and 
FK506, as well as the quantitation of fat in the stool. Most patients present 
satisfactory absorption curves for D-xylose, with values ranging between 15 
to 20 ng/dl within the first postoperative month. Absorption has increased 
over time as the transplanted bowel recovered motility and enteral feedings 
were advanced. Abnormal results were associated with increased stomal 
outputs and dysmotility; this has always prompted an aggressive search for 
reJectIOn. 
Though the excretion of fat in the stool has been abnormal in almost 
all patients, there have been no clinical implications to this phenomenon. 
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Fat can be provided as mean chain triglycerides in the enteral feeds and thus 
not require intact lymphatics. The absorption of FK506 was assessed by the 
maintenance of satisfactory blood trough levels off intravenous therapy. 
This occurred at a mean of about 28 days posroperatively. Recipients of 
multivisceral transplants tended to remain on IV therapy longer, however, 
the difference is not significant. The dose required to maintain adequate 
FK506 trough levels has been similar ro the standard liver transplant recipi-
ent. Total protein and albumin levels have improved in all surviving recipients. 
Radiologic evaluations were valuable in assessing the mucosal pattern 
and motility (Fig. 11.6A). Some evidence of mucosal edema can be seen in 
the presence of intestinal graft rejection. Severe rejection with exfoliation of 
the mucosa will ablate the normal mucosal pattern and be visualized as 
segments of "tubulized" intestine with intermittent strictures (Fig. 11.6B). 
Transit times vary between 30 minutes to 5 hours with a mean of 2 hours 
in intestinal allografts that were recovering satisfactorily. Dysmotility either 
as rapid transit or ileus has been seen with rejection. Abnormalities of the 
Fig. 11.6A. A normal appearing mucosal pattern in an intestinal al/ogra/t 
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native (recipient) gastrointestinal tract (stomach, duodenum) can be seen 
early on, and resolve over time. This may require a more prolonged period 
of tube alimentation. 
COMPLICATIONS 
Patients who undergo the combined liver/small bowel transplant re-
quire longer intensive care unit stay as well as a longer total hospital stay. 
Candidates for a liver/small bowel graft are generally in end stage liver 
disease with many of its associated morbidities. Infections and technical 
complications have occurred almost exclusively in the recipients of the liver/ 
small bowel graft. 
Infections have included bacterial, fungal and viral organisms. These 
may manifest as primary pulmonary, peritoneal, or venous catheter infec-
tions, or be part of a translocation phenomenon in a graft damaged by 
rejection. 26 Most deaths which have occurred have been related to infec-
tions. One recipient of 2 isolated intestinal grafts died of infectious compli-
cations after retransplantation. One child died following a biliary leak and 
sepsis; two children suffered disruption of the proximal intestinal anastomo-
sis and sepsis. One of these children also suffered hepatic artery thrombosis 
with fulminant hepatic gangrene, required a new liver graft, and eventually 
dyed of Influenza pneumonia; the other child presented a baseline immu-
nodeficiency disorder and developed Pneumocystis Carrinii pneumonia and 
probable graft versus host disease. 
Three patients have died of complic:ltions related to the treatment of 
their intestinal allograft rejection. One patient previously stated was an 
isolated small bowel recipient who died of infection after rerransplant. Another 
iso/;l£ed small bowel reCipient died of candida sepsis after salvage for a severe 
cxtoliative type intestinal allograft rejection. One pediatric recipient of a 
, , f '
fig. 11.68. Inlc5tmal al/owalt allcr scvere exfoliative tvpe relection shOWing a "Iubulizl'd" 
PJ lIern and 5 tnctures. 
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liver/small bowel graft suffered severe rejection of the intestine requiring 
OKT3, and then went on to develop severe adenovirus hepatitis of the liver 
graft. Though the intestinal portion of the allograft recovered, the severity 
of liver injury from the adenovirus infection required a combined liver! 
small bowel retransplantation. The child then went on to severely reject the 
intestinal allograft and did not respond to OKT3. He died of enterococcal 
sepsis and intestinal bleeding. 
Viral infections of most significance have included adenovirus and the 
Epstein-Barr virus in children and cytomegalovirus in the adults. One pa-
tient developed an unspecified viral encephalitis which required stopping 
the immunosuppression, then developed rejection of the intestinal allograft 
which required removal. 
Posttransplant lymphoproliferative disease (PTLD) has been seen in 3 
patients, all recipients of liver/small bowel grafts. These patients presented 
with multifocal disease and were treated with intravenous acyclovir or 
ganciclovir, as well as withholding of immunosuppression. One patient died 
of this complication. Two patients are presently recovering, however rejec-
tion of the intestinal allograft has occurred during the recovery phase, and 
has been treated successfully with steroids and reinstitution of FK506 im-
munosuppression. 
CONCLUSION 
Transplantation of the intestine has evolved into a feasible operation 
with satisfactory results. Overall patient survival is 79%, and overall graft 
survival is 73%. These survivors are free of TPN; the majority are home. 
Though this endeavor has required significant human and economic re-
sources, the encouraging results justifY further clinical trials. 
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